Vancouver, British Columbia — January 6, 2026 — Leads & Copy — BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) will participate in the YAFO Capital Access Asia 2025 Partnering Forum in San Francisco during JPM Week.
The biopharmaceutical company is focused on developing BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD) for neurological disorders. The YAFO Capital Access Asia Partnering Forum brings together life science companies, investors, pharmaceutical partners, and strategic advisors, with a focus on collaboration between North American and Asian capital and industry partners.
In addition to the YAFO Capital event on January 11th, Dr. Ahmad Doroudian, Chief Executive Officer, will attend the following events:
H7 Life science Investment Forum & China Night Reception on January 12th, WuXi Global Forum 2026 on January 13th, and DARPA and Ferocity Capital Biodefence Summit on January 13th.
Dr. Doroudian will represent BetterLife and be available for one-on-one meetings with investors, potential partners, and other stakeholders to discuss the company’s development strategy for BETR-001.
BETR-001, a neuroplastogen, is BetterLife’s patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, post traumatic stress disorder and cluster headache. Previous forms of 2-bromo-LSD has been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (Karst et al, Cephalgia 2010).
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
Parties interested in scheduling a meeting with BetterLife during the YAFO Capital Access Asia Partnering Forum are encouraged to contact Dr. Ahmad Doroudian at Ahmad.Doroudian@blifepharma.com or 1-604-221-0595.
BetterLife Pharma Inc. is focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, currently in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and is unregulated. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent covers treatment of various neurological disorders until around 2042.
Contact:
Ahmad Doroudian, Chief Executive Officer
Email: Ahmad.Doroudian@blifepharma.com
Phone: 1-604-221-0595
Source: BetterLife Pharma
